Comfort
Review results together
Ask what your results mean, whether further testing is needed and when they should be reviewed.
Symptom guide · Bleeding, Bladder, Pelvic & Hormone Conditions · Evidence-graded
Kidneys aren't the bladder. Why both deserve a look in midlife.
A kidney test result can leave questions hanging over meals, medicines or the next appointment. You can ask what the result means for you and which decisions, if any, need attention.
You do not have to make sense of a laboratory report alone.
What you might notice
A result or a change in your health may have raised questions.
What research tells us
KDIGO covers CKD evaluation, risk assessment, progression and complication management, and medication stewardship, using systematic reviews plus practice points.
A starting point
Ask what needs follow-up and when, rather than changing your routine yourself.
Start with what you've noticed and your own health history. Find guides for your body →
Search stays on this device
The KDIGO chronic kidney disease guideline covers evaluation, risk assessment, treatment and medication management. Ask which parts apply to your own situation.
The KDIGO guideline covers evaluation and risk assessment, management to delay chronic kidney disease progression and complications, and medication stewardship. Its recommendations draw on systematic evidence reviews and also include practice points.
You don't have to make the disruption look smaller to ask for help.
Get seen soon, or urgently if it's severe.
New swelling with breathlessness needs urgent assessment. Sudden or severe breathlessness, chest pain or fainting needs emergency help immediately.
This can mean the infection has reached the kidneys and needs same-day care.
Visible blood should always be checked. Persistent foamy urine can mean protein is leaking.
Stays on this device. It isn't sent to your account, Nila or anyone else. Three days describe what you noticed, not a diagnosis.
0 of 3 days logged.
Keep only the notes you find useful; bring them to your appointment.
Save laboratory reports and appointment notes, including any agreed follow-up.
Record symptoms or medication changes you would like to discuss at your review.
Options, not a to-do list.
Use these points to prepare a conversation about your care.
Comfort
Ask what your results mean, whether further testing is needed and when they should be reviewed.
Comfort
Ask a clinician or pharmacist to review your complete list before adding a supplement or changing treatment.
Comfort
Discuss food, fluids and activity with your care team rather than following a generic kidney-health plan.
Take this to your appointment.
Track a few days above to fill this in — or use the questions below as-is.
Pick an option in What tends to help above to add it here.
“These are interrupting ___. Would an examination or test help? What would it tell us, and what could we do without it?”
“Which option would you suggest for me, and what side effects or checks should I expect?”
“What should I notice after starting treatment, and when will we check in?”
Ask what any proposed test would help decide, who will explain the results, and when to return.
Same symptom, different doors.
Grades describe the recorded source type. A source listed here doesn't automatically support every sentence or every treatment.
Kidney Int · 2024
KDIGO covers CKD evaluation, risk assessment, progression and complication management, and medication stewardship, using systematic reviews plus practice points. The guideline is not intended for people receiving dialysis or kidney-transplant recipients.
Gravelsins et al · Science · 2026
Review mapping estrogen and progestogen receptors across organs, including this one. Narrative review, not a trial.
NICE · 2021
eGFR and urine albumin (ACR) testing, who should be checked, and blood pressure targets.
Beste et al · American Journal of Obstetrics and Gynecology · 2025
Eight observational studies; pooled unadjusted estimates found no overall recurrence increase. Doesn't prove a protective effect or settle aromatase inhibitor safety.
NICE NG23 · 2026
Start with non-hormonal care; recurrence risk remains uncertain in ER-positive cancer; involve a breast cancer specialist during aromatase inhibitor treatment.
North American Menopause Society (NAMS) · 2020
Faubion et al · NAMS / ISSWSH Consensus Recommendations · 2018
SOGC Clinical Practice Guideline No. 422b · 2024
Canadian guideline on genitourinary syndrome of menopause, including vaginal estrogen, moisturizers, lubricants and pelvic-floor considerations.
NHS · Official care guidance
Official care guidance for the linked warning: when to seek assessment or urgent help. This is not evidence of a menopause-specific cause or treatment.
North American Menopause Society (NAMS) · 2022
International Menopause Society (IMS) · 2024
NICE (UK National Institute for Health and Care Excellence) · 2024
Endocrine Society · 2015
Society of Obstetricians and Gynaecologists of Canada (SOGC) · 2024
SOGC's public-facing menopause resource, the Canadian counterpart to NAMS patient education.
Canadian Menopause Society · 2024
Canada's specialist society for menopause practitioners (formerly SIGMA); referenced by SOGC.
Cream, tablet or ring: what it helps, how long to use it, and after breast cancer.
The support device that's badly under-offered for prolapse and leaking.
U.S. Department of Veterans Affairs and Department of Defense · August 2026
U.S. VA/DoD guidance published August 2026, based on evidence reviewed through June 2025; supports individualized care rather than replacing clinical judgment.
U.S. Department of Veterans Affairs and Department of Defense · August 2026
U.S. VA/DoD guidance published August 2026, based on evidence reviewed through June 2025; supports individualized care rather than replacing clinical judgment.
This is a starting point, not a diagnosis or treatment plan.
Suggest a correction / Suggest a guide